专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2009125944A3 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER 审中-公开
标题翻译：含有非二氢吡啶钙通道阻断剂和血管紧张素-2受体阻滞剂的药物制剂
公开(公告)号：WO2009125944A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009001723
申请日：2009-04-03
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
IPC分类号： A61K9/22 , A61K31/435
CPC分类号： A61K31/435 , A61K9/0004 , A61K9/1676 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4178 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient and an extended-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. Since the disclosed formulation enables the release of the two ingredients at a different time, it reduces side effects and increases the effects of the drug more than the case of separately administering the ingredients each at the same time. In addition, the formulation maximizes the effects of drug at the time of day when the complication risk of cardiovascular system diseases is highest.
摘要翻译：本发明提供一种药物制剂，其包含含有作为药理活性成分的血管紧张素-2受体阻断剂（ARB）的速释隔室和含有非二氢吡啶钙通道阻断剂作为药理活性成分的缓释隔室。由于所公开的制剂能够在不同的时间释放两种成分，因此与分别同时分别给药成分的情况相比，它减少了副作用并增加了药物的作用。另外，当心血管系统疾病的并发症风险最高时，该制剂在一天中的时间最大化药物的作用。

12. 发明申请

WO2009125944A2 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER 审中-公开
标题翻译：含有非二氢脯氨酸钙通道阻断剂和血管紧张素-2受体阻断剂的药物制剂
公开(公告)号：WO2009125944A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001723
申请日：2009-04-03
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
IPC分类号： A61K9/22 , A61K31/435
CPC分类号： A61K31/435 , A61K9/0004 , A61K9/1676 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4178 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient and an extended-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. Since the disclosed formulation enables the release of the two ingredients at a different time, it reduces side effects and increases the effects of the drug more than the case of separately administering the ingredients each at the same time. In addition, the formulation maximizes the effects of drug at the time of day when the complication risk of cardiovascular system diseases is highest.
摘要翻译：本发明提供了包含含有作为药理活性成分的血管紧张素-2受体阻断剂（ARB）的立即释放室和含有非二氢吡啶类钙通道阻滞剂作为药理活性成分的延长释放室的药物制剂。由于所公开的配方使得能够在不同时间释放两种成分，所以与同时分别施用各成分的情况相比，其降低副作用并增加药物的效果。此外，当心血管系统疾病的并发症风险最高时，该制剂使药物的效果最大化。

13. 发明申请

WO2009038396A2 N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 审中-公开
标题翻译： N，N-二甲基咪唑二甲酰亚胺二酰胺二羧酸盐，生产该组合物的方法和包含该组合物的药物组合物
公开(公告)号：WO2009038396A2
公开(公告)日：2009-03-26
申请号：PCT/KR2008005574
申请日：2008-09-19
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , KIM YOUNG WOONG , KIM BYOUNG HA , KIM DUCK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , KIM YOUNG WOONG , KIM BYOUNG HA , KIM DUCK
IPC分类号： C07C279/26
CPC分类号： C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245
摘要： Disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N- dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.
摘要翻译：本文公开了N，N-二甲基亚氨基二甲酰亚胺二酰胺的新型二羧酸盐，其制备方法和包含其的药物组合物。更具体地，本文公开了N的新颖的二羧酸盐，N- dimethylimidodicarbonimidic二酰胺，通过允许N，N-二酰胺dimethylimidodicarbonimidic与特定的二羧酸，其具有改善的物理和化学性质，包括溶解度反应制备的结晶酸加成盐性，稳定性，非吸湿性和抗粘接性，低毒性，因此是在不仅糖尿病及其并发症的预防和治疗患者的所谓的代谢综合征非常有效的，其中糖尿病，肥胖症，高脂血症，脂肪肝，冠状动脉疾病，骨质疏松症，多囊性卵巢综合征等出现在组合，而且p53基因缺陷型癌症，肌肉疼痛，肌肉细胞毒性和横纹肌溶解，以及它们的制备方法和包含其的药物组合物。

14. 发明申请

WO2009134057A3 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER 审中-公开
标题翻译：含有血管紧张素II受体阻断剂的药物制剂
公开(公告)号：WO2009134057A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002225
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2081 , A61K9/2866 , A61K31/41 , A61K31/4178
摘要： The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.
摘要翻译：本发明提供含有血管紧张素-II受体阻断剂和作为药理活性成分的释放控制材料的药物制剂以及包含立即释放室和延长释放室的药物制剂。立即释放隔室含有作为预防和抑制肝炎的药理学活性成分的药剂，并且延长释放室具有血管紧张素-II受体阻断剂作为药理学活性成分。本发明的制剂使药物和临床上降低血压的效果最大化并且在服用制剂时预防并发症，有助于避免与由肝脏中的相同酶代谢的药物相互作用，并且预防和抑制药物的发生引起的药物长期引起的肝炎。

15. 发明申请

WO2009125981A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125981A3
公开(公告)日：2009-12-10
申请号：PCT/KR2009001822
申请日：2009-04-08
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
IPC分类号： A61K9/22 , A61K9/48 , A61K31/165 , A61K31/41 , A61K31/4178 , A61K31/4196 , A61P9/10
CPC分类号： A61K31/41 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/165 , A61K31/4178 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the compartments is an immediate-release compartment and the other one is an extended-release compartment. Since the disclosed formulation delivers the rennin inhibitor and angiotensin-II-receptor blocker at a specific delivery rate at a different time. It has an advantage in reducing the concern about side effects, improving drug effects, and simplifying the instructions for use of the drug. In addition, the formulation can pharmacologically, clinically, scientifically, and economically achieve more useful effects than the complex prescription case of taking the ingredients separately or each at once, in preventing and treating metabolic syndrome, cardiovascular disease and renal disease.
摘要翻译：本发明提供药物制剂，其包含含有作为药理学活性成分的肾素抑制剂的隔室和具有作为药理学活性成分的血管紧张素-II受体阻断剂的隔室。其中一个隔室是立即释放隔室，另一个隔室是延长释放隔室。由于所公开的制剂在不同的时间以特定的递送速率递送肾素抑制剂和血管紧张素-II-受体阻断剂。它在减少对副作用的关注，改善药物效果和简化药物使用说明方面具有优势。此外，该配方可以在药理学，临床，科学和经济上获得比单独或一次服用这些成分的复杂处方情况在预防和治疗代谢综合征，心血管疾病和肾病中更有用的效果。

16. 发明申请

WO2009125981A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125981A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001822
申请日：2009-04-08
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , SON JAE WOON , JO YOUNG GWAN
IPC分类号： A61K9/22 , A61K9/48 , A61K31/165 , A61K31/41 , A61K31/4178 , A61K31/4196 , A61P9/10
CPC分类号： A61K31/41 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/165 , A61K31/4178 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the compartments is an immediate-release compartment and the other one is an extended-release compartment. Since the disclosed formulation delivers the rennin inhibitor and angiotensin-II-receptor blocker at a specific delivery rate at a different time. It has an advantage in reducing the concern about side effects, improving drug effects, and simplifying the instructions for use of the drug. In addition, the formulation can pharmacologically, clinically, scientifically, and economically achieve more useful effects than the complex prescription case of taking the ingredients separately or each at once, in preventing and treating metabolic syndrome, cardiovascular disease and renal disease.
摘要翻译：本发明提供了包含含有作为药理活性成分的肾素抑制剂的隔室的药物制剂和具有作为药理活性成分的血管紧张素-II受体阻断剂的隔室。其中一个隔间是立即释放隔间，另一个是延长隔间。由于所公开的制剂在不同时间以特定的递送速率递送肾素抑制剂和血管紧张素-II-受体阻断剂。它有利于减少对副作用的关注，改善药物作用，并简化药物使用说明书。另外，与预防和治疗代谢综合征，心血管疾病和肾脏疾病有关的成分单独或每次立即使用的复杂处方情况下，该制剂在药理学，临床上，科学上和经济上都能获得更多的有用效果。

17. 发明申请

WO2009048289A3 PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS C VIRUS INFECTION COMPRISING HMG-COA REDUCTASE INHIBITOR AND BILE ACID 审中-公开
标题翻译：用于治疗包含HMG-COA还原酶抑制剂和胆汁酸的丙型肝炎病毒感染的药物组合物
公开(公告)号：WO2009048289A3
公开(公告)日：2009-06-04
申请号：PCT/KR2008005965
申请日：2008-10-10
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE JUN YOUNG
IPC分类号： A61K31/405 , A61K31/231 , A61K31/57 , A61P1/16 , A61P31/12 , C07K16/24
CPC分类号： A61K45/06 , A61K9/209 , A61K31/404 , A61K31/575 , A61K38/21 , A61K2300/00
摘要： Disclosed herein is a pharmaceutical composition for treating hepatitis C virus infection comprising an HMG-CoA reductase inhibitor and bile acid. More specifically, disclosed are a pharmaceutical composition for treating hepatitis C vims infection comprising fluvastatin or a pharmaceutically acceptable salt thereof along with ursodeoxycholic acid and a preparation method thereof.
摘要翻译：本文公开了用于治疗丙型肝炎病毒感染的药物组合物，其包含HMG-CoA还原酶抑制剂和胆汁酸。更具体而言，公开了用于治疗丙型肝炎病毒感染的药物组合物，其包含氟伐他汀或其药学上可接受的盐以及熊脱氧胆酸及其制备方法。

18. 发明申请

WO2009022821A3 COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME 审中-公开
标题翻译：包含HMG-COA还原酶和阿司匹林的抑制剂的组合制剂及其制备方法
公开(公告)号：WO2009022821A3
公开(公告)日：2009-04-09
申请号：PCT/KR2008004623
申请日：2008-08-08
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK
IPC分类号： A61K31/35
CPC分类号： A61K31/35 , A61K31/616 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.
摘要翻译：本发明涉及一种用于预防和治疗心血管疾病的时间疗法组合药物制剂，其基于以特定时间间隔施用多种药物的原则（即时间疗法）。具体地，组合的药物制剂包含HMG-CoA还原酶抑制剂，例如辛伐他汀和阿司匹林。因为组合的药物制剂是基于以特定时间间隔给药药物的原理而开发的，即所谓的时间疗法，与单独给药和单次制剂同时给药相比，它显示了预防或治疗心血管疾病的优异效果。此外，它是一种每日一次的剂型，其增加患者的药物依从性。特别是，尽管组合药物制剂中阿司匹林的含量降低，但组合药物制剂中阿司匹林的血小板聚集抑制作用等于现有技术中所用阿司匹林的量，而组合药物中阿司匹林制剂显示抗高血压作用。另外，按时间顺序组合的药物制剂允许两种彼此相互作用的药物长时间储存，并且组合的药物制剂确保了两种药物的人体安全性和功效。

19. 发明申请

WO2009134086A3 PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009134086A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002278
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Valsartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (5) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and an Iresartan-containing retarded release compartment, and (7) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Candesartan-containing retarded release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含有辛伐他汀的早期释放室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含有辛伐他汀的早期释放隔室和奥美沙坦的释放控制药物制剂（3）包含含有辛伐他汀的早期释放隔室和含缬沙坦的缓释隔室的释放控制药物制剂，（4）包含含有辛伐他汀的早期释放隔室的释放控制药物制剂，以及含有Candesartan的延迟释放隔室，（5）包含含有罗苏伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（6）包含含有罗苏伐他汀的早期释放的释放控制药物制剂隔间 d是含有Iresartan的缓释隔室，和（7）包含含有罗苏伐他汀的早期释放隔室和含有Candesartan的延迟释放隔室的释放控制药物制剂。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的特定组合制备的本发明的药物制剂与单一药物或简单组合药物相比显示出非常优异的治疗或预防疾病的效果。

20. 发明申请

WO2009134056A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134056A2
公开(公告)日：2009-11-05
申请号：PCT/KR2009002224
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG
IPC分类号： A61K9/22
CPC分类号： A61K9/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing hydrochlorothiazide as a pharmacologically active ingredient and an extended-release compartment containing losartan as a pharmacologically active ingredient. Since the formulation of the present invention can deliver hydrochlorothiazide and losartan at a specific rate at different times, it is very effective in treating hypertension and preventing complications, and has the effects of improving the adaptation rate of the patient, optimizing drug delivery time and reducing side effects.
摘要翻译：本发明提供了包含含有氢氯噻嗪作为药理活性成分的立即释放室和含有氯沙坦作为药理活性成分的延长释放室的药物制剂。由于本发明的制剂可以在不同时间以特定的速率递送氢氯噻嗪和氯沙坦，因此在治疗高血压和预防并发症方面非常有效，并且具有改善患者适应率，优化药物递送时间和减少副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式